Press Room

Press Clipping / Mar 31, 2020

Covid-19: Hand sanitiser effort continues

Speciality Chemicals Magazine, March 31, 2020

Covid-19: Hand sanitizer donated by Hovione | Hovione

Chemical companies continue to invest in hand sanitiser in response to the Covid-19 pandemic. A large number of them are now producing in significant volumes.

Ineos, the largest European producer of the two key raw materials - isopropyl alcohol (IPA) and ethanol – has announced its intention to produce 1 million bottles of hand sanitiser/month from each of three newly built facilities in the UK, Germany and France.

As of the end of March, the company has hit its target of building the first plant near Middlesbrough, UK. It will supply hospitals free of charge “during the crisis period” and is in discussions with retailers.

Dow announced on 30 March that its sites at Auburn, Michigan; South Charleston, West Virginia; Seneffe, Belgium; and Hortolândia, Brazil “possess the necessary raw material handling, mixing and packaging capabilities and will produce hand sanitiser”. They join the site at Stade, Germany, which is already manufacturing it.

Dow, like Ineos, was already producing raw materials, said that it could adapt its capabilities for downstream production with “little to no impact to normal operations”. Auburn can produce 7 tonnes/week and similar volumes are expected at the other sites. Once all are at full production, the company expects to produce 200 tonnes.

All of the hand sanitiser that will be produced has been allocated, with the majority for donation to state and regional health systems and government agencies for distribution. It will also be distributed to Dow production sites to help protect frontline employees. The first deliveries are expected to begin in the first week of April.

Plant-based ingredients firm Roquette has adapted one of its pilot lines at its site in Lestrem, France, to manufacture about 5,000 litres/week of a hydro-alcoholic disinfectant solution. The first shipments were sent to Lille University Hospital Centre, the French Blood Donors Organisation and to other local health facilities, in coordination with the Hauts-de-France Regional Health Agency and the local authorities.

In Germany, Wacker donated 15,000 litres of hand sanitiser for the production of disinfectants to Bavarian hospitals and care facilities at the request of the state Ministry of Economic Affairs. The alcohol needed, 11,000 liters of 2-propanol, was transported from Nünchritz, Saxony, to the Gendorf chemical industry park in Bavaria to be mixed and sent to an official distribution centre.

Swiss pharmaceutical CMDO Siegfried is also supplying disinfectant in those regions where it operates production sites, including the Swiss cantons of Aargau and Valais and around Minden in Germany. “The service including delivery is free of charge to the extent possible,” the company said, adding that it will not supply private or commercial organisations.

Meanwhile, Croda International said that it has gifted enough glycerine to regular customers to manufacture five million 250 ml bottles of hand sanitiser, assuming 2% glycerine content. It is also donating saponin vaccine adjuvants to projects working on a vaccine. The company plans to review with customers where more glycerine could be gifted.

Similarly in the US, Amyris, which is in discussions for the testing of its fermentation-derived squalene as a vaccine adjuvant for a Covid-19 vaccine, has launched its own No Compromise Pipette Baby branded hand sanitiser. The company said that it “will not price its hand sanitiser at a premium, and plans to donate part of the supply to front-line health staffers and medical personnel”. It plans to produce 30,000 units in the first few weeks.

Portugal’s Hovione began producing IPA- and ethanol-based hand sanitiser to a WHO formulation at tonne-scale for itself when supplies were short, it has emerged. The company, another major pharmaceutical CDMO, is now supplying the material free to Portuguese hospitals. Volumes were expected to reach 30 tonnes by the end of the month.

Earlier in March, Lanxess added a second shift at its site in Sudbury, UK, to boost production of Vikron sanitiser. Earlier, BASF announced plans to produce hand sanitisers at Ludwigshafen and supply them to hospitals in the Rhine-Neckar metropolitan region. The company has now reallocated tonnes of raw materials, especially IPA, for making the sanitisers and secured legal official permission to make them.

Similarly, Huntsman and Syngenta began making hydro alcoholic solution to produce hand sanitiser at Monthey, Switzerland, for free-of-charge supply to hospitals and pharmacies in the Canton of Vaud and the General Hospital in Lausanne. Plans were to ramp up production to 3-5 tonnes/week. Arkema has repurpose da production line at its Rhône-Alpes Research Centre in order to make 20 tonnes/week of alcohol-based solution to be distributed free of charge for the mass restocking of public hospitals.

The effort is not limited to chemical companies, of course. Flavours and fragrance giant Firmenich has shifted production at La Plaine, Switzerland, to disinfectant solution, while luxury goods maker LVMH and many manufacturers and distillers of spirits on both sides of the Atlantic have also switched production.

 

Read the article at Specchemonline

 

 

Also in the Press Room

See All

ViSync® Technologies, a joint venture between Hovione, a global specialist integrated CDMO and leader in spray drying and particle engineering, and iBET (Instituto de Biologia Experimental e Tecnológica), a not-for-profit R&D institution specializing in Biotechnology and Life Sciences, is proud to announce the appointment of Elsa Abranches as its Chief Scientific Officer (CSO). Headquartered in Oeiras, Portugal, ViSync® Technologies was established to address unmet technological needs in the pharmaceutical industry, focusing on developing innovative solutions for the cell and gene therapy space. By leveraging Hovione's expertise in pharmaceutical development, particle engineering, and industrialization, alongside iBET’s pioneering research in biotechnological sciences, ViSync® is uniquely equipped to drive innovation in targeted delivery and stabilization of next-generation therapies.  Dr. Elsa Abranches brings over two decades of experience in cell and gene therapy, with a strong track record of leading diverse teams in dynamic environments. In her new role as ViSync® CSO, she will drive the company’s R&D strategy and scientific vision, positioning ViSync® as a leader in innovation within the dynamic and rapidly advancing field of cell and gene therapy. “We are thrilled to welcome Elsa Abranches as Chief Scientific Officer of ViSync®,” said Dr. Christoph Bruecher, Chairman of the Board of ViSync® and VP Business Transformation at Hovione. “Her expertise and vision in the field of advanced therapeutics will be pivotal in driving ViSync’s mission to create transformative solutions that empower pharmaceutical companies and improve patient treatment outcomes.” Dr. Manuel Carrondo, Director of the Board of ViSync® and Vice President of iBET, added, “Elsa’s appointment underscores our commitment to establishing ViSync® as a leader in cell and gene therapy innovation. Her scientific leadership will be critical as we tackle some of the most pressing challenges in the field of new modalities drug delivery.” Elsa Abranches, new Chief Scientific Officer of ViSync®, said: “Having worked in different countries and industries, I’m thrilled to bring my experience back home to join ViSync®. This new venture represents an incredible opportunity to collaborate with local and international partners to drive innovation in advanced therapeutics and help shape the future of life-changing therapies”.     About Hovione Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices. Hovione's culture is based on innovation, quality and dependability. Hovione is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.   About iBET iBET is a private non-profit institution devoted to biotechnology research, with 35 years of experience creating and transferring knowledge to the global biopharma and biotech sectors. iBET’s core expertise lies on the development of bioprocesses and analytical tools for Advanced Therapeutic Medicinal Products (ATMPs), including cell and gene therapies, vaccines, antibodies and other innovative therapeutic products. Leveraged by the emerging areas of Data Science and Translational Immunology, we offer bespoke R&D services from early-stage R&D to GMP manufacturing. iBET’s infrastructure comprises cutting-edge laboratories, a GMP certified Analytical Services Unit, and a Late-Stage R&D and Bioproduction Unit, covering upstream and downstream process development, bioanalytical tools for critical quality attribute monitoring, to scale-up and tech transfer. iBET also hosts satellite laboratories of major pharmaceutical companies and serves as an incubation platform for start-up/spin-off companies. iBET is driven by its innovative and agile culture of continuous improvement and a strong sense of ambition, ownership and commitment in developing and delivering the best solutions to our stakeholders.     

News

ViSync® Technologies appoints Elsa Abranches as Chief Scientific Officer

Dec 19, 2024

International pharmaceutical contract development and manufacturing organisation (CDMO) Hovione has today officially commissioned an expansion at its manufacturing facility in Ringaskiddy. The multi-million euro investment almost doubles the capacity of Hovione’s spray drying facilities in Ireland and will create more than 20 new positions. Hovione said this latest investment reinforces the company's position as a global leader in spray drying for pharma applications.   This manufacturing technology, the company explained, is "especially important for inhalable therapies and oral medications with low bioavailability, enabling more effective treatments".  Deputising for the Mayor of the County of Cork, councillor Audrey Buckley said:  “I am delighted to welcome this very significant investment and the creation of further highly skilled jobs in Cork today.  “It reinforces Hovione’s commitment to the region and the innovative solutions it provides to the pharmaceutical industry in Ireland.” Meanwhile Michael McGrath, the European Commissioner-Designate for Democracy, Justice and the Rule of Law, welcomed the expected jobs boost the expansion is to create.  “This latest investment highlights the success of Hovione’s facility in Ringaskiddy, and underlines the continued resilience of Ireland’s pharmaceutical manufacturing sector.  “I am delighted that Hovione will be shortly welcoming new team members to this expanded facility, and I wish both them and Hovione every success”. Jean-Luc Herbeaux, Hovione's chief executive said: “This newly opened facility further strengthens Hovione's position as the global CDMO of choice for spray drying development and manufacturing services.  “It also underscores our commitment to bringing first-in-class technology and world-leading manufacturing services to Irish shores.  “Ireland provides a superior environment for pharmaceutical manufacturing, and we are delighted to be a part of it.” CEO of IDA Ireland, Michael Lohan, said Hovione "has made a significant contribution both locally and nationally through employment and investment alike". "We warmly welcome Hovione’s commitment to investing in Cork and we wish them continued success," he added.    Read the full article on EchoLive.ie    

Press Clipping

Pharma company announces expansion of Cork facility to create more than 20 new jobs

Nov 25, 2024

Pharmaceutical contract development and manufacturing company Hovione has officially commissioned an expansion at its manufacturing facility in Ringaskiddy, Cork.  Announcing the development on Monday, the multi-million euro investment almost doubles the capacity of Hovione’s spray drying facilities in Ireland and will create more than 20 new positions. This manufacturing technology is especially important for inhalable therapies and oral medications with low bioavailability, enabling more effective treatments, the company said. Deputising for the Mayor of the County of Cork, Cllr. Audrey Buckley said: “I am delighted to welcome this very significant investment and the creation of further highly skilled jobs in Cork today.  "It reinforces Hovione’s commitment to the region and the innovative solutions it provides to the pharmaceutical industry in Ireland.”  Michael McGrath, the European Commissioner-Designate for Democracy, Justice and the Rule of Law said: “This latest investment highlights the success of Hovione’s facility in Ringaskiddy, and underlines the continued resilience of Ireland’s pharmaceutical manufacturing sector. "I am delighted that Hovione will be shortly welcoming new team members to this expanded facility, and I wish both them and Hovione every success”. This latest investment builds on the momentum of the recently announced spray drying capacity expansion at the Company's East Windsor, New Jersey, site.  Jean-Luc Herbeaux, Hovione´s Chief Executive said: “This newly opened facility further strengthens Hovione´s position as the global CDMO of choice for spray drying development and manufacturing services.  "It also underscores our commitment to bringing first-in-class technology and world-leading manufacturing services to Irish shores. Ireland provides a superior environment for pharmaceutical manufacturing, and we are delighted to be a part of it.” IDA chief executive Michael Lohan said the company has made a significant contribution both locally and nationally, adding: "I am pleased to be here today to mark another step on that journey. We warmly welcome Hovione’s commitment to investing in Cork and we wish them continued success.”   Read the full article on IrishExaminer.com  

Press Clipping

Pharma company Hovione to double capacity at Cork site as part multi-million euro investment

Nov 25, 2024